A phase III study to evaluate 24- and 48-week response-guided treatment with telaprevir in combination with VX 222, pegylated interferon alpha 2a, and ribavirin in patients with genotype 1 chronic hepatitis C and who have not responded (partial and null responders) to at least one prior course of treatment with pegylated interferon alpha 2a and ribavirin alone.

Trial Profile

A phase III study to evaluate 24- and 48-week response-guided treatment with telaprevir in combination with VX 222, pegylated interferon alpha 2a, and ribavirin in patients with genotype 1 chronic hepatitis C and who have not responded (partial and null responders) to at least one prior course of treatment with pegylated interferon alpha 2a and ribavirin alone.

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2011

At a glance

  • Drugs Interferon alpha-2a; Lomibuvir; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top